Evaluation of PD-L1 Expression in Colorectal Carcinomas by Comparing Scoring Methods and Their Significance in Relation to Clinicopathologic Parameters
Mirela Frančina,
Mislav Mikuš,
Marin Mamić,
Tihomir Jovanović,
Mario Ćorić,
Božica Lovrić,
Ivan Vukoja,
Goran Zukanović,
Kristijan Matković,
Jasmina Rajc,
Ferdinand Slišurić,
Mateja Jurić-Marelja,
Goran Augustin,
Ilijan Tomaš
Affiliations
Mirela Frančina
Požega General Hospital, 34000 Požega, Croatia
Mislav Mikuš
Department of Obstetrics and Gynecology, University Hospital Centre Zagreb, 10000 Zagreb, Croatia
Marin Mamić
Požega General Hospital, 34000 Požega, Croatia
Tihomir Jovanović
Faculty of Medicine, University of J.J. Strossmayer, 31000 Osijek, Croatia
Mario Ćorić
Department of Obstetrics and Gynecology, University Hospital Centre Zagreb, 10000 Zagreb, Croatia
Božica Lovrić
Požega General Hospital, 34000 Požega, Croatia
Ivan Vukoja
Požega General Hospital, 34000 Požega, Croatia
Goran Zukanović
Požega General Hospital, 34000 Požega, Croatia
Kristijan Matković
Požega General Hospital, 34000 Požega, Croatia
Jasmina Rajc
Faculty of Medicine, University of J.J. Strossmayer, 31000 Osijek, Croatia
Ferdinand Slišurić
Požega General Hospital, 34000 Požega, Croatia
Mateja Jurić-Marelja
Požega General Hospital, 34000 Požega, Croatia
Goran Augustin
Department of Surgery, University Hospital Centre Zagreb, 10000 Zagreb, Croatia
Ilijan Tomaš
Faculty of Medicine, University of J.J. Strossmayer, 31000 Osijek, Croatia
Background: This study aims to evaluate PD-L1 expression in colorectal carcinomas (CRCs) by using the tumor proportion score (TPS) and the combined positive score (CPS), and to investigate whether there is a correlation with clinicopathologic features. Methods: A cross-sectional study was conducted that included samples from patients with colorectal adenocarcinoma treated with colon resection and rectal resection after neoadjuvant radio- and chemotherapy at the Department of Abdominal Surgery at Požega Hospital in the period from 2017 to 2022. The study included 102 tumor tissue samples from patients after resection and the pathohistological diagnosis of adenocarcinoma. Results: In our study, the PD-L1 positivity rate after the TPS was 42 (41%) samples, and after the CPS, 97 (95%) of them (p 50%, compared with other lymph node statuses. Conclusions: These results suggest that the total number of PD-L1-expressing cells, including tumor and immune cells, is a more sensitive biomarker than the number of PD-L1-expressing tumor cells alone in CRC.
